Literature DB >> 14982050

Reduced full-field electroretinogram (ERG) in a patient treated with methotrexate.

Vesna Ponjavic1, Lotta Gränse, Elisabeth Bengtsson Stigmar, Sten Andréasson.   

Abstract

PURPOSE: To examine retinal function in a patient with decreased vision possibly due to treatment with methotrexate.
METHODS: Ophthalmological examination included testing of visual acuity (VA), fundus inspection, fundus photography, and kinetic perimetry. Retinal function was tested objectively with three electrophysiological methods: full-field electroretinography (ERG), multifocal electroretinography (mfERg) and also electro-oculography (EOG).
RESULTS: A 13-year-old boy with psoriasis arthritis had been treated with methotrexate on a weekly basis for 8.5 years. After terminating treatment, his VA, which was reduced to 0.3 in both eyes initially, improved during the following 3 years but did not return to normal. No visual field defects were found with kinetic perimetry. The rod and cone responses in the full-field ERG were markedly reduced in b-wave amplitude initially, but grew slowly to nearly normal values 3 years later. After withdrawal of the drug, the mfERG demonstrated normal responses in the macular region. The Arden index in the EOG was normal.
CONCLUSION: Chronic treatment with methotrexate may affect VA, and mat reversible reduce rod and cone function. In patients who use systemic medication and who vision is reduced, objective evaluation of retinal function with electrophysiological methods is recommended.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982050     DOI: 10.1046/j.1600-0420.2003.00181.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  2 in total

1.  Electrophysiologic evaluation of retinal function in patients with psoriasis and vitiligo.

Authors:  Nasser Shoeibi; Ahmad Reza Taheri; Malihe Nikandish; Arash Omidtabrizi; Nasim Khosravi
Journal:  Doc Ophthalmol       Date:  2014-01-19       Impact factor: 2.379

Review 2.  Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.

Authors:  V Peponis; V C Kyttaris; S E Chalkiadakis; S Bonovas; N M Sitaras
Journal:  Lupus       Date:  2010-02-09       Impact factor: 2.911

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.